Close Menu

NEW YORK – Oncolytics Biotech on Tuesday said that it has partnered with Roche and German medical oncology group AIO to evaluate its immuno-oncolytic virus pelareorep and the anti-PD-L1 checkpoint inhibitor atezolizumab (Roche's Tecentriq) in various gastrointestinal cancers.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.